EPCAM and breast carcinoma: Considering that the number of EpCAM-CK7/8-CD24+N-cadherin- CCs was increased in patients with distant metastasis during the follow-up period, we determined the cutoff point of CD45-EpCAM-CK7/8-CD24+N-cadherin- CCs count with the highest prognostic value for distant metastases in M0 breast cancer patients using ROC analysis (AUC 0.91 (0.79–1.00), p = 0.0006, sensitivity—85.7%, specificity—78.4%) (Fig. 8).